1. Home
  2. DTST vs RNTX Comparison

DTST vs RNTX Comparison

Compare DTST & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data Storage Corporation

DTST

Data Storage Corporation

HOLD

Current Price

$4.29

Market Cap

32.5M

Sector

Technology

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTST
RNTX
Founded
2001
2001
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.5M
30.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DTST
RNTX
Price
$4.29
$1.17
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
20.0K
120.9K
Earning Date
03-30-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
8036.56
N/A
EPS
1.89
N/A
Revenue
$25,529,819.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.35
N/A
Revenue Growth
260.19
N/A
52 Week Low
$2.93
$1.02
52 Week High
$5.44
$2.96

Technical Indicators

Market Signals
Indicator
DTST
RNTX
Relative Strength Index (RSI) 43.08 40.75
Support Level $4.10 $1.11
Resistance Level $4.95 $1.22
Average True Range (ATR) 0.27 0.12
MACD -0.00 -0.02
Stochastic Oscillator 35.88 9.47

Price Performance

Historical Comparison
DTST
RNTX

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: